INTRODUCTION In this article, we report the data regarding treatment adherence of a group of patients with multiple sclerosis (MS) and relapsing-remitting or secondary progressive disease who were followed in the MS outpatient clinic of Bozyaka Education and Research Hospital, Izmir. METHODS We collected the demographic data of 219 patients with MS who were treated with immunomodulatory drugs...

Glatiramer acetate (GA) is a drug that commonly is used for the treatment of relapsing-remitting multiple sclerosis (RRMS). Although it typically is known as a safe and effective therapy, a number of adverse effects associated with GA have been reported in the literature. Local injection-site reactions (LISRs) and mild systemic symptoms are among the most commonly described adverse effects. A r...

We discuss the case of a patient with Progressive Multifocal Leukoencephalopathy (PML), developed after treatment with Natalizumab for 42 months for relapsing remitting multiple sclerosis (RRMS). Imaging was consistent with wide-spread PML with features that portended a high risk of development of Immune Reconstitution Inflammatory Syndrome (IRIS). After completion of plasmapheresis, she was st...

BACKGROUND The relationship between white matter injury and cortical atrophy development in relapsing-remitting multiple sclerosis (RRMS) remains unclear. OBJECTIVES To investigate the associations between corticospinal tract integrity and cortical morphology measures of the primary motor cortex in RRMS patients and healthy controls. METHODS 51 RRMS patients and 30 healthy controls underwen...

The treatment of multiple sclerosis (MS) has changed over the last 20 years. All immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a medical challenge in MS to develop a treatment for progressive forms. The most common injectable disease-modifying therapies in RRMS include β-interferons 1a or 1b and glatiramer acetate. However, one of the major challenges of inje...

The pathogenesis of multiple sclerosis (MS) is thought to involve peripheral activation of immune cells against central nervous system (CNS) antigens and their migration across the blood-brain barrier, leading to CNS inflammation and neurodegeneration. Alemtuzumab, a humanized anti-CD52 monoclonal antibody that rapidly depletes CD52-expressing cells from the circulation, is being investigated a...

Natalizumab, a humanized monoclonal antibody against very late antigen-4 (VLA-4), inhibits the transmigration of immune cells across the bloodbrain barrier into the central nervous system (CNS). However, progressive multifocal leukoencephalopathy (PML) is caused following natalizumab treatment in patients with relapsing remitting multiple sclerosis (RRMS). The reason for higher PML prevalence i...

Fingolimod (FTY) is the first oral medication approved for treatment of relapsing-remitting multiple sclerosis (RRMS). Its effectiveness and safety were confirmed in several phase III clinical trials, but proper evaluation of safety in the real patient population requires long-term post-marketing monitoring. Since the approval of FTY for RRMS in Japan in 2011, it has been administered to approx...

This study investigated the ability of patients with Relapsing-Remitting Multiple Sclerosis (RRMS) to recognize emotional facial expressions. Cognitive deterioration, depression, alexithymia and facial expression recognition ability were assessed in fiftyfive patients and twenty-one controls. Facial expression recognition ability was measured by a forced-choice labeling procedure of five emotio...

Uncertainty exists as to whether similar or different mechanisms contribute to the pathogenesis of different subtypes of multiple sclerosis (MS). Detailed analysis of naive T cell homeostasis shows that patients with relapsing-remitting MS (RRMS) and with primary progressive MS (PPMS) have early-onset thymic involution that causes reduced thymic output. The reduced thymic output leads to second...